Status: Not yet recruiting
Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DLBCL-NOS
Evaluation of the Safety and Efficacy of Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DLBCL-NOS.
Participants needed: 25
Trial details
Phase: Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: The First Affiliated Hospital with Nanjing Medical UniversityUpdated: Sep 30, 2025Locations: 1
Eligibility criteria
BV+DLBCL, NOS diagnosed by pathological diagnosis according to WHO 2016 classifi... [+12]
Patients who meet any of the following criteria will be excluded from the study： [+19]